DNA-mediated immunization of glycoprotein 350 of Epstein-Barr virus induces the effective humoral and cellular immune responses against the antigen

Sojin Jung, Young Kwan Chung, Sun Hwa Chang, Ju Kim, Hak Ryul Kim, Hyon Seok Jang, Jeong Chae Lee, Gook Hyun Chung, Yong Suk Jang

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Epstein-Barr virus (EBV) is a human pathogen that is involved in numerous diseases and tumors. Since the EBV infection occurs in the early ages of life, and most of the population is subsequently exposed to EBV, the conventional method of vaccination to induce the prophylactic immunity cannot be considered effective in coping with the virus infection. In this study, we tested whether the injection of a plasmid vector that contained the gene for glycoprotein 350 (gp350), which had been identified as a ligand for virus' adsorption and a target for virus neutralizing antibodies, could induce effective immune responses against the antigen. As a result, the injection of the constructed plasmid vector into mice induced the production of gp350-specific antibodies. A major isotype of the gp350-specific antibodies was IgG1. The antibodies efficiently mediated the antibody-dependent cellular cytotoxicity against the cells expressing the gp350 antigen. In addition, the injection of the constructed plasmid vector stimulated the precursor T cell population that was specific to the gp350 antigen. In addition, gp350-specific cytotoxic T lymphocytes were efficiently stimulated by the injection of the constructed plasmid vector. These results suggested that the injection of the plasmid vector, containing the gp350 gene of Epstein-Barr virus, could be one of the most effective ways to induce both prophylactic and therapeutic vaccinations against the virus infection.

Original languageEnglish
Pages (from-to)41-49
Number of pages9
JournalMolecules and Cells
Volume12
Issue number1
Publication statusPublished - 2001 Aug 31

Fingerprint

Histocompatibility Antigens Class II
Humoral Immunity
Human Herpesvirus 4
Cellular Immunity
Immunization
Glycoproteins
Plasmids
DNA
Injections
Antibodies
Virus Diseases
Vaccination
T-Lymphoid Precursor Cells
Viruses
Antigens
Epstein-Barr Virus Infections
Cytotoxic T-Lymphocytes
Neutralizing Antibodies
Population
Genes

Keywords

  • Antibody
  • Cytotoxic T Lymphocyte
  • DNA Vaccine
  • Epstein-Barr Virus
  • gp350

ASJC Scopus subject areas

  • Medicine(all)
  • Molecular Biology
  • Cell Biology

Cite this

DNA-mediated immunization of glycoprotein 350 of Epstein-Barr virus induces the effective humoral and cellular immune responses against the antigen. / Jung, Sojin; Chung, Young Kwan; Chang, Sun Hwa; Kim, Ju; Kim, Hak Ryul; Jang, Hyon Seok; Lee, Jeong Chae; Chung, Gook Hyun; Jang, Yong Suk.

In: Molecules and Cells, Vol. 12, No. 1, 31.08.2001, p. 41-49.

Research output: Contribution to journalArticle

Jung, Sojin ; Chung, Young Kwan ; Chang, Sun Hwa ; Kim, Ju ; Kim, Hak Ryul ; Jang, Hyon Seok ; Lee, Jeong Chae ; Chung, Gook Hyun ; Jang, Yong Suk. / DNA-mediated immunization of glycoprotein 350 of Epstein-Barr virus induces the effective humoral and cellular immune responses against the antigen. In: Molecules and Cells. 2001 ; Vol. 12, No. 1. pp. 41-49.
@article{ae03be713be04832961f2c1c63b18780,
title = "DNA-mediated immunization of glycoprotein 350 of Epstein-Barr virus induces the effective humoral and cellular immune responses against the antigen",
abstract = "Epstein-Barr virus (EBV) is a human pathogen that is involved in numerous diseases and tumors. Since the EBV infection occurs in the early ages of life, and most of the population is subsequently exposed to EBV, the conventional method of vaccination to induce the prophylactic immunity cannot be considered effective in coping with the virus infection. In this study, we tested whether the injection of a plasmid vector that contained the gene for glycoprotein 350 (gp350), which had been identified as a ligand for virus' adsorption and a target for virus neutralizing antibodies, could induce effective immune responses against the antigen. As a result, the injection of the constructed plasmid vector into mice induced the production of gp350-specific antibodies. A major isotype of the gp350-specific antibodies was IgG1. The antibodies efficiently mediated the antibody-dependent cellular cytotoxicity against the cells expressing the gp350 antigen. In addition, the injection of the constructed plasmid vector stimulated the precursor T cell population that was specific to the gp350 antigen. In addition, gp350-specific cytotoxic T lymphocytes were efficiently stimulated by the injection of the constructed plasmid vector. These results suggested that the injection of the plasmid vector, containing the gp350 gene of Epstein-Barr virus, could be one of the most effective ways to induce both prophylactic and therapeutic vaccinations against the virus infection.",
keywords = "Antibody, Cytotoxic T Lymphocyte, DNA Vaccine, Epstein-Barr Virus, gp350",
author = "Sojin Jung and Chung, {Young Kwan} and Chang, {Sun Hwa} and Ju Kim and Kim, {Hak Ryul} and Jang, {Hyon Seok} and Lee, {Jeong Chae} and Chung, {Gook Hyun} and Jang, {Yong Suk}",
year = "2001",
month = "8",
day = "31",
language = "English",
volume = "12",
pages = "41--49",
journal = "Molecules and Cells",
issn = "1016-8478",
publisher = "Korean Society for Molecular and Cellular Biology",
number = "1",

}

TY - JOUR

T1 - DNA-mediated immunization of glycoprotein 350 of Epstein-Barr virus induces the effective humoral and cellular immune responses against the antigen

AU - Jung, Sojin

AU - Chung, Young Kwan

AU - Chang, Sun Hwa

AU - Kim, Ju

AU - Kim, Hak Ryul

AU - Jang, Hyon Seok

AU - Lee, Jeong Chae

AU - Chung, Gook Hyun

AU - Jang, Yong Suk

PY - 2001/8/31

Y1 - 2001/8/31

N2 - Epstein-Barr virus (EBV) is a human pathogen that is involved in numerous diseases and tumors. Since the EBV infection occurs in the early ages of life, and most of the population is subsequently exposed to EBV, the conventional method of vaccination to induce the prophylactic immunity cannot be considered effective in coping with the virus infection. In this study, we tested whether the injection of a plasmid vector that contained the gene for glycoprotein 350 (gp350), which had been identified as a ligand for virus' adsorption and a target for virus neutralizing antibodies, could induce effective immune responses against the antigen. As a result, the injection of the constructed plasmid vector into mice induced the production of gp350-specific antibodies. A major isotype of the gp350-specific antibodies was IgG1. The antibodies efficiently mediated the antibody-dependent cellular cytotoxicity against the cells expressing the gp350 antigen. In addition, the injection of the constructed plasmid vector stimulated the precursor T cell population that was specific to the gp350 antigen. In addition, gp350-specific cytotoxic T lymphocytes were efficiently stimulated by the injection of the constructed plasmid vector. These results suggested that the injection of the plasmid vector, containing the gp350 gene of Epstein-Barr virus, could be one of the most effective ways to induce both prophylactic and therapeutic vaccinations against the virus infection.

AB - Epstein-Barr virus (EBV) is a human pathogen that is involved in numerous diseases and tumors. Since the EBV infection occurs in the early ages of life, and most of the population is subsequently exposed to EBV, the conventional method of vaccination to induce the prophylactic immunity cannot be considered effective in coping with the virus infection. In this study, we tested whether the injection of a plasmid vector that contained the gene for glycoprotein 350 (gp350), which had been identified as a ligand for virus' adsorption and a target for virus neutralizing antibodies, could induce effective immune responses against the antigen. As a result, the injection of the constructed plasmid vector into mice induced the production of gp350-specific antibodies. A major isotype of the gp350-specific antibodies was IgG1. The antibodies efficiently mediated the antibody-dependent cellular cytotoxicity against the cells expressing the gp350 antigen. In addition, the injection of the constructed plasmid vector stimulated the precursor T cell population that was specific to the gp350 antigen. In addition, gp350-specific cytotoxic T lymphocytes were efficiently stimulated by the injection of the constructed plasmid vector. These results suggested that the injection of the plasmid vector, containing the gp350 gene of Epstein-Barr virus, could be one of the most effective ways to induce both prophylactic and therapeutic vaccinations against the virus infection.

KW - Antibody

KW - Cytotoxic T Lymphocyte

KW - DNA Vaccine

KW - Epstein-Barr Virus

KW - gp350

UR - http://www.scopus.com/inward/record.url?scp=0035980158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035980158&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 41

EP - 49

JO - Molecules and Cells

JF - Molecules and Cells

SN - 1016-8478

IS - 1

ER -